

Current Price Sept' 04, 2018 **Rp 850**
Fair Value **Rp 925**
Potential Upside **8,82%**

HOLD

Stock Information

Ticker Code **SIDO**
Sector **Pharmacy**
Market Cap (IDR) **12.75 T**
52-Week High (IDR) **920**
52-Week Low (IDR) **540**
Shares Issued **15.00 B**

Major Shareholders (%)

PT Hotel Candi Baru **81.00%**
Public **19.00%**

Price Performance (2017-2018)



Source: Bloomberg

Rifqiyati
Rifqiyati@oso-securities.com

PT OSO Securities


Cyber 2 Tower,
Jl. H.R. Rasuna Said Blok X-5 No. 13
Setiabudi
Jakarta 12950
Tel. : 021 2991 5300
Fax : 021 2902 1497

Update : PT Industri Jamu Dan Farmasi Sido Muncul Tbk (SIDO IJ), (SIDO JK)

- Per Juni Laba Bersih SIDO Melonjak 16,8% Menjadi Rp 291 Milliar Dibanding Periode Yang Sama Tahun Lalu**
Seiring dengan keberhasilan SIDO dalam meningkatkan penjualan menjadi Rp1,27 triliun serta meningkatkan efisiensi fasilitas produksi ekstraksi. Dimana kontribusi terbesar penjualan disokong oleh lini herbal dan suplemen yakni sebesar 7,4%.
- Realisasi Capex Tahun Ini Sudah Mencapai 54,43% atau sekitar Rp 163,3 miliar**
Hingga semester I 2018, realisasi dana belanja modal (capex) SIDO mencapai 54,43% atau sekitar Rp 163,3 miliar dari total capex yang dialokasikan sepanjang tahun 2018 yang sebesar Rp 300 miliar.
- Target Peroleh Laba Tahun Ini Diyakini Lebih Tinggi Dibanding Tahun 2017 Lalu**
Seiring dengan adanya usaha SIDO dalam memperluas penjualan baik di dalam negeri maupun di luar negeri, raihan laba bersih SIDO tahun ini diyakini mampu melebihi dari Rp 600 miliar. Angka ini tentunya lebih tinggi dibanding dengan perolehan laba bersih tahun 2017 lalu yang hanya mencapai Rp 533,79 miliar.
- Pelemahan Mata Uang Dalam Negeri Tidak Akan Berpengaruh Signifikan Terhadap Bisnis SIDO**
Tahun 2018 SIDO optimis bisnisnya tidak akan terlalu terganggu oleh pelemahan mata uang Rupiah yang terjadi saat ini. Hal ini mengingat bahwa 95% dari penjualan produk SIDO merupakan penjualan di dalam negeri, sementara untuk penjualan di luar negeri hanya 5% di mana salah negara yang menjadi tujuannya adalah Nigeria.
- Tetap Inovatif dan Ekspansif di Tahun 2018**
SIDO telah mengeluarkan produk baru Tolak Angin dan Tolak Linu yakni berbentuk *soft capsule*, dimana produk ini merupakan yang pertama dan menjadi harapan SIDO untuk bisa memperluas segmentasi pasar. Selain itu, saat ini SIDO telah membangun pabrik *soft capsule* di Semarang, dimana nilai investasi mencapai Rp 15 miliar.
- Valuasi dan Rekomendasi**
Kami memberikan rekomendasi HOLD untuk kode saham SIDO dengan *fair value* senilai Rp 925,- dan *potential upside* sebesar 8.82%. Dasar perhitungan menggunakan metode valuasi yaitu DCF (*Discounted Cash Flow*) menggunakan asumsi *terminal growth* sebesar 4% dan WACC 9.5%.


Share Value Indicator

Grafik I : Historic - EPS




Source : Bloomberg LP and OSO Research

Grafik II : Historic - PER (SIDO)




Source : Bloomberg LP and OSO Research

Grafik III : Historic - Book Value




Source : Bloomberg LP and OSO Research

Grafik IV : Historic - PBV (SIDO)



Source : Bloomberg LP and OSO Research

Grafik V : WACC (%)



Source : Bloomberg LP and OSO Research


Prospect SIDO masih memiliki fundamental yang cukup bagus seiring dengan kualitas produk serta potensi pertumbuhan volume produksi. Penambahan produksi ini terjadi atas peningkatan kapasitas produksi jamu cair dan *soft capsule*. Kami perkirakan tahun ini SIDO mampu mencetak kinerja keuangan yang lebih baik dibandingkan tahun 2017.

Performa Kinerja Keuangan SIDO Semester I 2017

Pada 1H18, SIDO membukukan laba bersih senilai Rp 291 miliar dari periode yang sama tahun sebelumnya Rp 244 miliar


Pada paruh pertama tahun ini SIDO cukup berprestasi, pasalnya meski kondisi perekonomian kurang stabil SIDO tetap bisa membuktikan peningkatan kinerja keuangan yang lebih baik. Tercermin dari raihan laba bersih SIDO di semester I tahun ini yang lebih tinggi dibanding periode yang sama tahun lalu yakni menjadi Rp 291 miliar dari sebelumnya Rp 244 miliar, angka itu setara dengan kenaikan sebesar 16,8%. Hal ini sejalan dengan pendapatan penjualan SIDO yang meningkat diikuti adanya efisiensi beban pokok penjualan sebesar 5%. Selain itu, kenaikan laba juga didorong oleh keberhasilan SIDO dalam meningkatkan efisiensi fasilitas produksi ekstraksi.

Grafik VI : Net Income (Bn.IDR)



Source : Bloomberg LP and OSO Research


Grafik VII : Net Income 1H18 (Bn.IDR)



Source : Bloomberg LP and OSO Research


Semester I tahun ini hampir sama dengan periode sama tahun lalu, dimana lini herbal dan suplemen masih menjadi kontributor terbesar terhadap penjualan SIDO. Pertumbuhan penjualan lini ini mencapai 7,4% yang juga diikuti oleh kenaikan pertumbuhan penjualan pada lini makanan dan minuman serta farmasi yang masing-masing mengalami kenaikan sebesar 0,4% dan 10,9%. Dari laporan kinerja keuangan SIDO, tercatat untuk pendapatan bersih SIDO semester I 2018 sendiri sebesar Rp 1,27 triliun atau meningkat 5,4% dibandingkan dengan periode yang sama tahun sebelumnya yang hanya mencapai Rp 1,21 triliun.

Grafik VIII : Sales (Bn.IDR)



Source : Bloomberg LP and OSO Research

Grafik IX : Sales (Bn.IDR)




Source : Bloomberg LP and OSO Research

Tabel I : Sales - Breakdown (Bn.IDR)

| Sales Product (Bn, IDR) | 2015 | 2016 | 2017 | 2018F | 2019F | 2020F |
|-------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Jamu Herbal | 1,145.73 | 1,518.87 | 1,690.35 | 1,985.88 | 2,184.46 | 2,466.79 |
| Makanan dan Minuman | 996.77 | 963.20 | 794.97 | 810.87 | 827.09 | 843.63 |
| Farmasi | 76.04 | 79.73 | 88.52 | 92.94 | 97.59 | 102.47 |
| Total Sales | 2,218.54 | 2,561.81 | 2,573.84 | 2,889.69 | 3,109.14 | 3,412.89 |

Source : Bloomberg LP and OSO Research

Diagram I : Sales Contribution




Diperkirakan tahun ini segmen Jamu Herbal masih mendominasi penjualan SIDO sebesar 69%, diikuti segmen makanan dan minuman sebesar 28% dan sisanya dikontribusi segmen farmasi sebesar 3%.

Source : Bloomberg LP and OSO Research


Selain dari sisi laba dan pendapatan penjualan, hingga akhir Juni 2018 aset SIDO dibukukan sebesar Rp 3,49 triliun dimana angka ini lebih tinggi dibanding periode akhir Juni 2017 yang hanya tercatat Rp 2,80 triliun. Sementara, ada kenaikan yang cukup signifikan dari posisi liabilitas perusahaan jamu ini di semester I 2018 dibandingkan dengan periode semester I 2017. Tercatat liabilitas SIDO naik dari sebelumnya hanya Rp 185,69 miliar menjadi Rp 739,77 miliar diikuti dengan posisi modal SIDO yang naik tipis menjadi Rp 2,75 triliun menjadi Rp 2,62 triliun.

Grafik X : Total Assets (Bn.IDR)



Source : Bloomberg LP and OSO Research

Grafik XI : Total Liabilities and Equity (Bn.IDR)



Source : Bloomberg LP and OSO Research

Financial Projection

Tabel II : Income Statement (Bn.IDR)

| In Billions of IDR | 2015 | 2016 | 2017 | 2018F | 2019F | 2020F |
|--------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Sales | 2,218.5 | 2,561.8 | 2,573.8 | 2,889.7 | 3,109.1 | 3,412.9 |
| Cost of Sales | (1,335.2) | (1,494.1) | (1,411.9) | (1,531.5) | (1,678.9) | (1,843.0) |
| Gross Profit | 883.4 | 1,067.7 | 1,162.0 | 1,358.2 | 1,430.2 | 1,569.9 |
| Operating Expenses | | | | | | |
| Selling Expenses - Dep | (303.0) | (370.2) | (364.2) | (408.9) | (439.9) | (482.9) |
| General Exp - Dep | (101.9) | (138.0) | (172.0) | (203.4) | (218.2) | (238.6) |
| Other Operating Income | 13.1 | 23.4 | 17.4 | 19.6 | 21.1 | 23.1 |
| Other operating Expense | (1.9) | (4.5) | (2.9) | 3.3 | 3.5 | 3.9 |
| Total Opex | (393.7) | (489.4) | (521.7) | (589.4) | (633.5) | (694.5) |
| EBIT | 489.6 | 578.3 | 640.2 | 768.7 | 796.7 | 875.4 |
| Other Income/Expense | | | | | | |
| Finance Income | 70.8 | 50.9 | 42.2 | 42.2 | 42.2 | 42.2 |
| Financial Expenses | (0.1) | (0.1) | (0.6) | (0.7) | (0.7) | (0.7) |
| Total | 70.8 | 50.8 | 41.7 | 41.6 | 41.6 | 41.6 |
| Profit Before Tax | 560.4 | 629.1 | 681.9 | 810.3 | 838.2 | 917.0 |
| Tax Expense | (122.9) | (148.6) | (148.1) | (176.0) | 209.6 | 229.2 |
| Net income current year | 437.5 | 480.5 | 533.8 | 634.3 | 1,047.8 | 1,146.2 |

Source : Bloomberg LP and OSO Research

Tabel III : Cash Flow (Bn.IDR)

| In Billions of IDR | 2015 | 2016 | 2017 | 2018F | 2019F | 2020F |
|--------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Operating Cash Flow | | | | | | |
| Net Income | 437.47 | 480.53 | 533.80 | 634.30 | 1,047.80 | 1,146.22 |
| Dep. & Amort. | 68.63 | 53.22 | 58.29 | 68.13 | 52.23 | 28.73 |
| Change In Working Cap. | 161.04 | 118.45 | (37.45) | 245.49 | (49.03) | (26.66) |
| Others | (33.23) | (13.35) | 101.21 | 8.18 | (92.32) | (3.60) |
| Total CFO | 633.92 | 638.84 | 655.85 | 956.10 | 958.68 | 1,144.70 |
| Investment Cash Flow | | | | | | |
| Capex | (239.42) | (142.57) | (222.24) | (250.41) | (191.98) | (105.59) |
| Chg. In Other Asset | 41.96 | (15.46) | (171.85) | (6.74) | (13.54) | (33.68) |
| Total CFI | (197.47) | (158.03) | (394.10) | (257.14) | (205.52) | (139.27) |
| Free Cash Flow | 436.45 | 480.81 | 261.75 | 698.95 | 753.16 | 1,005.43 |
| Financing Cash Flow | | | | | | |
| Change in Capital | - | 13.38 | 0.23 | - | - | - |
| Dividend Paid | (360.00) | (368.50) | (386.97) | (543.46) | (601.28) | (916.94) |
| Other Equity Components | (104.76) | 42.98 | 2.00 | 59.79 | - | - |
| Adjustments | 0.42 | (8.80) | (11.08) | (11.08) | (11.08) | (11.08) |
| Chg in Other Liabilities | 0.08 | 0.31 | 39.78 | (0.46) | (0.42) | (0.38) |
| Total CFF | (464.27) | (320.65) | (356.04) | (495.20) | (612.78) | (928.40) |
| Net Cash Flow | (27.82) | 160.16 | (94.28) | 203.75 | 140.38 | 77.03 |
| Cash Beginning | 864.79 | 836.98 | 997.14 | 902.85 | 1,106.60 | 1,246.98 |
| Cash Ending | 836.97 | 997.14 | 902.85 | 1,106.60 | 1,246.98 | 1,324.01 |

Source : Bloomberg LP and OSO Research

Tabel IV: Income Statement (Bn.IDR)

| In Billions of IDR | 2015 | 2016 | 2017 | 2018F | 2019F | 2020F |
|--|----------------|----------------|----------------|----------------|----------------|----------------|
| Cash & equivalent | 837.0 | 997.1 | 902.9 | 1,106.6 | 1,247.0 | 1,324.0 |
| Trade Receivables | 347.7 | 387.2 | 431.5 | 346.8 | 373.2 | 409.6 |
| Inventory | 265.0 | 317.1 | 267.9 | 160.8 | 201.5 | 221.2 |
| Advance | 7.2 | 4.1 | 3.5 | 3.9 | 4.2 | 4.7 |
| Prepaid Expenses | 12.6 | 32.6 | 8.2 | 9.3 | 10.0 | 10.9 |
| Prepaid Taxes | 48.0 | 51.0 | 14.9 | 16.7 | 18.0 | 19.8 |
| Total Current Asset | 1,517.4 | 1,789.1 | 1,628.9 | 1,644.2 | 1,853.9 | 1,990.2 |
| Advance for purchase of property, plant and equipment | 17.1 | 37.7 | 166.6 | 158.3 | 145.6 | 131.1 |
| Other Non-Current Financial Assets | - | 8.1 | 45.8 | 50.4 | 55.4 | 61.0 |
| Fixed Asset | 961.9 | 1,051.2 | 1,215.2 | 1,397.5 | 1,537.2 | 1,614.1 |
| Goodwill | 91.4 | 91.4 | 91.4 | 91.4 | 91.4 | 91.4 |
| Others | 18.3 | 5.1 | 10.3 | 20.8 | 41.9 | 84.6 |
| Total Non-Current Asset | 1,088.7 | 1,193.5 | 1,529.3 | 1,718.3 | 1,871.6 | 1,982.1 |
| Total Asset | 2,606.1 | 2,982.6 | 3,158.2 | 3,362.5 | 3,725.5 | 3,972.3 |
| Current Liabilities | | | | | | |
| Trade Payables | 147.8 | 177.9 | 124.9 | 176.4 | 193.4 | 221.5 |
| Other Payables | 10.5 | 5.5 | 11.1 | 13.3 | 14.3 | 15.7 |
| Advance from customers | 0.4 | 0.7 | - | - | - | - |
| Accrued Expense | 3.3 | 2.8 | 36.7 | 41.5 | 44.6 | 48.9 |
| Corporate income tax | 8.3 | 7.7 | - | - | - | - |
| Other Taxes | 13.2 | 20.1 | 35.8 | 42.5 | (50.6) | (55.4) |
| Unearned revenue | 0.6 | 1.1 | - | - | - | - |
| Total Current Liabilities | 184.1 | 215.7 | 208.5 | 273.7 | 201.7 | 230.7 |
| Non-Current Liabilities | | | | | | |
| Deferred Tax Liabilities | 0.2 | - | 8.8 | 9.2 | 9.7 | 10.2 |
| Other Payables Third Parties | - | - | - | - | - | - |
| Employee Benefit - Long Term | 13.6 | 14.0 | 45.0 | 44.1 | 43.2 | 42.4 |
| Total Non-Current Liab. | 13.7 | 14.0 | 53.8 | 53.4 | 52.9 | 52.6 |
| Equity | | | | | | |
| Capital Stock | 1,500.0 | 1,500.0 | 1,500.0 | 1,500.0 | 1,500.0 | 1,500.0 |
| Paid In Capital | 692.4 | 705.8 | 706.0 | 706.0 | 706.0 | 706.0 |
| Appropriated | 57.8 | 127.2 | 220.8 | 94.0 | 143.3 | 168.0 |
| Unappropriated | 158.0 | 419.9 | 469.1 | 735.5 | 1,121.6 | 1,315.1 |
| Total Equity | 2,408.3 | 2,752.9 | 2,895.9 | 3,035.4 | 3,470.9 | 3,689.1 |
| Total Liabilities & Equity | 2,606.1 | 2,982.6 | 3,158.2 | 3,362.5 | 3,725.5 | 3,972.3 |

Source : Bloomberg LP and OSO Research

Research Team

| | | |
|---|--------------------|------------------|
| Ike Widiawati (ike@oso-securities.com) | Head of Research | +62 21 2991 5300 |
| Rifqiyati (Rifqiyati @oso-securities.com) | Research Analyst | +62 21 2991 5300 |
| Sukarno Alatas (sukarno@oso-securities.com) | Research Analyst | +62 21 2991 5300 |
| Mochammad Cahyo (cahyo@oso-securities.com) | Research Associate | +62 21 2991 5300 |
| Istavani Kayesha (istavani@oso-securities.com) | Research Associate | +62 21 2991 5300 |

Disclosure Of Interests

As of the date of this report,

- The research analysts primarily responsible for the preparation of all or part of this report hereby certify that:
 - the views expressed in this research report accurately reflect the personal views of each such analyst about the subject securities and issuers; and
 - no part of the analyst's compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed in this research report.
- The research analysts primarily responsible for the preparation of all or part of this report, or his/her associate(s), do not have any interest (including any direct or indirect ownership of securities, arrangement for financial accommodation or serving as an officer) in any company mentioned in this report
- PT OSO Securities Indonesia on a business in Indonesia in investment banking, proprietary trading or agency broking in relation to securities

Disclaimer

This report has been prepared by PT OSO Sekuritas Indonesia on behalf of itself and its affiliated companies and is provided for information purposes only. Under no circumstance is it to be used or considered as an offer to sell, or a solicitation of any offer to buy. This report has been produced independently and the forecasts, opinions and expectations contained herein are entirely those of PT. OSO Sekuritas Indonesia. We expressly disclaim any responsibility or liability (express or implied) of PT. OSO Sekuritas Indonesia, its affiliated companies and their respective employees and agents whatsoever and howsoever arising (including, without limitation for any claims, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this report and neither PT. OSO Sekuritas Indonesia, its affiliated companies or their respective employees or agents accepts liability for any errors, omissions or mis-statements, negligent or otherwise, in the report and any liability in respect of the report or any inaccuracy therein or omission there from which might otherwise arise is hereby expressly disclaimed. The information contained in this report is not to be taken as any recommendation made by PT. OSO Sekuritas Indonesia or any other person to enter into any agreement with regard to any investment mentioned in this document. This report is prepared for general circulation. It does not have regard to the specific person who may receive this report. In considering any investments you should make your own independent assessment and seek your own professional financial and legal advice.

PT OSO Sekuritas Indonesia - Research
Cyber 2 Tower, 22nd Floor
Jl. HR. Rasuna Said Blok X-5 No. 13
Jakarta Selatan, 12950
Telp: +62-21-299-15-300
Fax : +62-21-290-21-497